pentoxifylline has been researched along with Peripheral Arterial Disease in 9 studies
Peripheral Arterial Disease: Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the efficacy, safety and tolerability of propionyl-L-carnitine (PLC) in patients with intermittent claudication in the Chinese population." | 9.17 | A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. ( Chen, Z; Jin, B; Li, J; Li, K; Li, L; Liu, C; Luo, T; Yang, B; Zhang, J; Zhang, X; Zheng, Q, 2013) |
| "We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management." | 7.80 | Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. ( Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2014) |
| "This study investigated the efficacy, safety and tolerability of propionyl-L-carnitine (PLC) in patients with intermittent claudication in the Chinese population." | 5.17 | A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. ( Chen, Z; Jin, B; Li, J; Li, K; Li, L; Liu, C; Luo, T; Yang, B; Zhang, J; Zhang, X; Zheng, Q, 2013) |
| "This study was designed to evaluate hemorheological changes in patients with cerebrovascular disease (CVD) and peripheral arterial disease (PAD) after 4 weeks of pentoxifylline therapy as well as to study red blood cell microrheological variables after the cell incubation with pentoxifylline and some phosphodiesterase (PDE) activity inhibitors." | 5.15 | Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment. ( Bulaeva, SV; Miloradov, MJ; Muravyov, AV; Tikhomirova, IA; Uzikova, EV; Zamishlayev, AV, 2011) |
| "Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding." | 3.88 | Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. ( Alzamora, M; Forés, R; Giner-Soriano, M; Heras, A; Marsal, JR; Morros, R; Pera, G; Real, J; Ribes, E; Serna, MC, 2018) |
| "We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management." | 3.80 | Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. ( Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Real, J | 1 |
| Serna, MC | 1 |
| Giner-Soriano, M | 1 |
| Forés, R | 1 |
| Pera, G | 1 |
| Ribes, E | 1 |
| Alzamora, M | 1 |
| Marsal, JR | 1 |
| Heras, A | 1 |
| Morros, R | 1 |
| Luo, T | 1 |
| Li, J | 1 |
| Li, L | 1 |
| Yang, B | 1 |
| Liu, C | 1 |
| Zheng, Q | 1 |
| Jin, B | 1 |
| Chen, Z | 1 |
| Li, K | 1 |
| Zhang, X | 1 |
| Zhang, J | 1 |
| Bernát, SI | 1 |
| Agrawal, K | 1 |
| Eberhardt, RT | 1 |
| McDermott, MM | 1 |
| Kibbe, MR | 1 |
| Kuznetsov, MR | 1 |
| Rodionov, SV | 1 |
| Koshkin, VM | 1 |
| Virganskiĭ, AO | 1 |
| Golosnitskiĭ, PIu | 1 |
| Tepliakov, SA | 1 |
| Kosykh, IV | 1 |
| Ostapchuk, NA | 1 |
| Lisenkov, OP | 1 |
| Chernikov, VP | 1 |
| Squires, H | 2 |
| Simpson, E | 2 |
| Meng, Y | 2 |
| Harnan, S | 2 |
| Stevens, J | 1 |
| Wong, R | 1 |
| Thomas, S | 2 |
| Michaels, J | 2 |
| Stansby, G | 2 |
| Muravyov, AV | 1 |
| Bulaeva, SV | 1 |
| Tikhomirova, IA | 1 |
| Zamishlayev, AV | 1 |
| Uzikova, EV | 1 |
| Miloradov, MJ | 1 |
| Stevens, JW | 1 |
| O'Donnell, ME | 1 |
2 reviews available for pentoxifylline and Peripheral Arterial Disease
| Article | Year |
|---|---|
Contemporary medical management of peripheral arterial disease: a focus on risk reduction and symptom relief for intermittent claudication.
Topics: Ankle Brachial Index; Cilostazol; Combined Modality Therapy; Exercise Therapy; Humans; Intermittent | 2015 |
A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
Topics: Cilostazol; Cost-Benefit Analysis; Humans; Intermittent Claudication; Nafronyl; Nicotinic Acids; Pen | 2011 |
3 trials available for pentoxifylline and Peripheral Arterial Disease
| Article | Year |
|---|---|
A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
Topics: Administration, Oral; Aged; Carnitine; Double-Blind Method; Humans; Intermittent Claudication; Middl | 2013 |
[Effectiveness of pentoxifylline and of bio-electromagnetic therapy in lower limb obliterative arterial disease].
Topics: Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Combined Modality Therapy; Electromagnetic Phe | 2013 |
Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.
Topics: 1-Methyl-3-isobutylxanthine; Adult; Aged; Anemia; Blood Transfusion; Erythrocytes; Erythropoietin; F | 2011 |
4 other studies available for pentoxifylline and Peripheral Arterial Disease
| Article | Year |
|---|---|
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Cerebrovascular Disorders; Cilostazol; | 2018 |
Improving Lower Extremity Functioning in Peripheral Artery Disease: Exercise, Endovascular Revascularization, or Both?
Topics: Adult; Cilostazol; Combined Modality Therapy; Endovascular Procedures; Exercise Test; Exercise Thera | 2017 |
[Role of low-dose acetylsalicylic acid in comprehensive postoperative treatment of patients with lower-limb chronic arterial insufficiency].
Topics: Aspirin; Blood Coagulation; Blood Viscosity; Femoral Artery; Graft Occlusion, Vascular; Humans; Lowe | 2011 |
Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
Topics: Cilostazol; Cost-Benefit Analysis; Decision Support Techniques; Humans; Intermittent Claudication; M | 2014 |